Aridis Pharmaceuticals, Inc. (ARDS)
Chart Events
Performance Outlook
| Previous Close | 1.8300 |
| Open | 1.8000 |
| Bid | 1.8100 x 4000 |
| Ask | 1.8400 x 800 |
| Day's Range | 1.8000 - 1.8900 |
| 52 Week Range | 0.8800 - 4.3400 |
| Volume | |
| Avg. Volume | 126,825 |
| Market Cap | 25.859M |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.9530 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.33 |
- Zacks
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2022.
- Benzinga
Aridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action
Aridis Pharmaceuticals Inc's (NASDAQ: ARDS) inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in the lungs of infected non-human primates. The candidate also protected their lungs from disease. AR-701 was effective in non-human primates when used either as a prophylactic or therapeutic treatment regimen. Inhaled AR-701 substantially reduced and continued to suppress the viral load in the nasal sinus and oropharynx (upper respirato
